Compare InMode Ltd (INMD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Viatris Inc — how do they compare? InMode Ltd trades at $15.25 (market cap $872.08M), while Viatris Inc trades at $16.12 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 21.4× InMode Ltd's market cap, and Viatris Inc pays a 2.95% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | VTRS | |
|---|---|---|
Market Cap | $872.08M | $18.69B |
Sector | Technology | Health |
52-Week High | $16.62 | $17.86 |
52-Week Low | $12.76 | $9.49 |
Enterprise Value | $375.42M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.24, up 0.33% on the day, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company maintains strong profitability with a 20.69% net income margin and attractive valuation ratios, including a P/E of 12.52. Recent news highlights include Q2 2026 results consistent with the prior year and an unsolicited acquisition proposal from Steel Partners at $16.75 per share.
The stock presents a value opportunity given its low valuation multiples and high margins, but faces near-term uncertainty from shareholder activism, a securities fraud investigation, and potential acquisition volatility. Analyst sentiment is divided between Buy and Hold ratings, reflecting the balance between fundamental strength and corporate governance concerns.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
